There are 712 papers on NLRP3 in aging research: 22 trials and 41 observational studies in people, 421 in animals, 44 in cells, 178 reviews. The newest story, Nov 19, 2026: “Hydrogen sulfide may ease signs of heart aging in mice”.
NLRP3 deletion extends lifespan in a study of high-fat-fed mice and reduces age-related cardiac and vascular damage in mouse experiments; independent labs also reproduce NLRP3-induced senescence in human cells. Yet macrophage experiments show NLRP3 supports senescent-cell clearance in mice, and it protects against atherosclerosis in Ldlr-deficient mice. Some registered trials across uses ended over a year ago without posted results.
191 findings in 142 papers from 2012 to 2026, 22 of them since May 2026
The findings reach people, from one lab or study; independent labs found the same change in cells and mice. 155 independent labs in 23 countries; 24 trials, 5 with no results posted.
“S100A8/A9 and NLRP3 co-occurrence was confirmed across 75,132 patients (log2 OR 2.56-2.59; p<0.01).”
Cells and mice: replicated by independent labs. Humans: a single group. Worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
Includes the processes named after it and trials of drugs aimed at it.
155 independent labs in 23 countries
2 findings against
24 trials, 5 with no results posted
Funders: National Natural Science Foundation of China and others
10 of 295 findings with company ties
20 of 24 trials sponsored by developers of drugs aimed at it
Human trial22
Humans41
Animals421
Cells44
In silico3
Interventions
43
Atorvastatin
↓downin mice1↓downin rats1
2 studies
Atorvastatin decreases NLRP3 in rats (acetic acid-induced colitis).
“decreased expression of colonic mTOR, NLRP3, DKK1, IL-6, TNF-α, and STAT3”
High-intensity interval training decreases NLRP3 in humans (low-compression (1:1 work-to-rest) versus baseline).
“Both NLRP3 and H19 experienced a significant drop only with LC in comparison to the baseline.”
Human triallow-compression (1:1 work-to-rest) versus baselinelow-compression, 1:1 work-to-rest, home-based2-4 sets of 8 exercises at 80%-95% HRmax, twice a week8 weeksmales
High-intensity interval training showed no clear effect on NLRP3 in humans.
“No significant change was found for the fold amount of NLRP3 and H19, although LC was the only exercise program that reduced these markers compared to baseline (both, p < 0.01, 0.14 ≤ ES ≤0.27; Figure ).”
“NOD-like receptor protein 3 (NLRP3), a key regulator of the innate immune response, initiates inflammation by recognizing pathogens and damage-related molecular patterns.”
NLRP3 induces inflammation in neurodegenerative disorders.
“aberrant NLRP3 activation drives persistent neuroinflammation, leading to synaptic dysfunction and neuronal loss through the sustained release of mature IL-1β and IL-18”
NLRP3 increases inflammation in mice (shown by knockout).
“deletion of NLRP3 improves some behavioral and biochemical characteristics associated with aging, such as signal memory, neuroinflammation, and metabolic inflammation, but not anxious behavior”
“Activation of the NLRP3 inflammasome results in maturation of caspase-1, which processes pro-inflammatory cytokines IL-1β and IL-18, as well as GSDMD.”
mitochondrial reactive oxygen species activates NLRP3.
“We then examine the mechanisms by which mitochondrial reactive oxygen species activate the NLRP3 inflammasome and NF-κB pathways to drive the senescence-associated secretory phenotype.”
Mitochondrial reactive oxygen species activates NLRP3 in aged individuals.
“NLRP3 inflammasome is over-activated in aged individuals, through deficient mitochondrial functioning, increased mitochondrial Reactive Oxigen Species (mtROS) and/or mitochondrial (mt)DNA”
SIRT3 decreases NLRP3 in cells (shown by loss of Sirt3 in senescent macrophages, basal and LPS-induced).
“a decrease in the expression of Sirtuin3 (Sirt3), which in turn leads to increased basal and lipopolysaccharides (LPS)-induced protein expression of NLRP3”
Cellsshown by loss of Sirt3 in senescent macrophages, basal and LPS-inducedmacrophages
“the increase in NAD+ levels and the activation of SIRT2 expression can reduce the expression of NLRP3, Gasdermin D (GSDMD), Caspase-1, IL-18, and IL-1β in the ovary.”
Older age is associated with NLRP3 in mice (ApoE −/− mice).
“By 12 months of age, compared with 3 months, ApoE −/− mice also demonstrate increased expression of the inflammasome-associated cytosolic protein NLRP3”
AnimalsApoE −/− miceaortic endothelium compared with perivascular endotheliumfemales
NLRP3 is associated with kidney disease in humans (association depends on disease).
“Although genetic and pharmacological studies support a pathogenic role in experimental models, clinical evidence remains largely associative and disease-dependent.”
NLRP3 is associated with exceptional longevity in humans (restrained NLRP3 inflammasome activation).
“Exceptional longevity also appears to depend on limiting the detrimental consequences of chronic inflammation through delayed or better-controlled inflammaging, restrained NLRP3 inflammasome activation and preserved capacity to buffer oxidative stress.”
lysosomal dysfunction is associated with NLRP3 in aged chondrocytes with ageing-related lysosomal impairment.
“lysosomal dysfunction under these conditions has increasingly been associated with the amplification of the senescence-associated secretory phenotype (SASP), activation of the NLRP3 inflammasome”
Reviewin aged chondrocytes with ageing-related lysosomal impairment
In mice exposed to D-galactose, a hydrogen sulfide-releasing compound reduced signs of heart aging and activation of a protein involved in inflammation.In mice exposed to D-galactose, a hydrogen sulfide-releasing compound reduced signs of heart aging and activation of a protein involved in inflammation.
Heart artery disease odds were slightly higher, with an odds ratio of 1.06 per genetically predicted 19% decrease in a blood inflammation marker.Heart artery disease odds were slightly higher, with an odds ratio of 1.06 per genetically predicted 19% decrease in a blood inflammation marker.
An experiment in male mice with surgically induced disease compared packages released by human joint-lining stem cells from young and aged donors.An experiment in male mice with surgically induced disease compared packages released by human joint-lining stem cells from young and aged donors.
Reducing a circular RNA weakened the compound’s effects in male mice given it in drinking water for 16 weeks.Reducing a circular RNA weakened the compound’s effects in male mice given it in drinking water for 16 weeks.
Cardiovascular conditions affected 28.2% of cancer survivors with obesity, versus 15.6% of adults with obesity alone, despite lower levels of an inflammation marker.Cardiovascular conditions affected 28.2% of cancer survivors with obesity, versus 15.6% of adults with obesity alone, despite lower levels of an inflammation marker.